NCEL

NASDAQ 已收盘

NewcelX

2.54 USD
▼-0.15-5.58%
盘后 2.48 -2.36%
2026-11-20
市值
$14.67M
市盈率
—
EPS
-0.51
股息率
—
52 周区间
1.83 – 5.12
成交量
5.61K
Beta
0.57
目标价
—
52W 低 1.8352W 高 5.12
价格走势

公司简介

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep dis...